FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents using 5-(2,4-dihydroxy-5- isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof for preparing a pharmaceutical composition used for treating bladder cancer, colon cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, pancreatic cancer, stomach cancer, gastro-intestinal cancer, prostate cancer, head and neck cancer and/or blood cancer.
EFFECT: invention refers to treating the number of cancers using 5-(2,4-dihydroxy-5- isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide.
6 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| COMBINATION OF 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTICOLIC ACTIVITY, WITH MEK INHIBITOR | 2013 |
|
RU2684407C2 |
| CANCER TREATMENT | 2005 |
|
RU2389507C2 |
| RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | 2016 |
|
RU2697703C2 |
| HYDROXYBENZAMIDE DERIVATIVES AND USE THEREOF AS Hsp90 INHIBITORS | 2006 |
|
RU2458919C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| MEDICATIONS FOR CANCER TREATMENT | 2008 |
|
RU2481830C2 |
